{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:31:21Z","timestamp":1791217881422,"version":"4.1.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1053\/j.ajkd.2021.01.015","type":"journal-article","created":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T11:30:31Z","timestamp":1616671831000},"page":"272-281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"title":["Posttransplant Lymphoproliferative Disorder Following Kidney Transplantation: A Review"],"prefix":"10.1053","volume":"78","author":[{"given":"Ben","family":"Sprangers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo V.","family":"Riella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan","family":"Dierickx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.ajkd.2021.01.015_bib1","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/j.1600-6143.2011.03896.x","article-title":"Epidemiology of posttransplant lymphoproliferative disorders in adult kidney and kidney pancreas recipients: report of the French registry and analysis of subgroups of lymphomas","volume":"12","author":"Caillard","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1053\/j.ajkd.2021.01.015_bib2","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/ndt\/gfx356","article-title":"Incidence and predictors of post-transplant lymphoproliferative disease after kidney transplantation during adulthood and childhood: a registry study","volume":"33","author":"Francis","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2021.01.015_bib3","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ajh.21911","article-title":"Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States","volume":"86","author":"Quinlan","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1053\/j.ajkd.2021.01.015_bib4","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1093\/ndt\/gfr769","article-title":"Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients","volume":"27","author":"Sampaio","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2021.01.015_bib5","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/TP.0000000000002378","article-title":"Elevated risk of cancer after solid organ transplant in childhood: a population-based cohort study","volume":"103","author":"Kitchlu","year":"2019","journal-title":"Transplantation"},{"key":"10.1053\/j.ajkd.2021.01.015_bib6","first-page":"990","article-title":"Posttransplant malignancies in solid organ adult recipients: an analysis of the U.S","volume":"94","author":"Sampaio","year":"2012","journal-title":". National Transplant Database. Transplantation"},{"key":"10.1053\/j.ajkd.2021.01.015_bib7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0140-6736(07)61050-2","article-title":"Incidence of cancers in people with HIV\/AIDS compared with immunosuppressed transplant recipients: a meta-analysis","volume":"370","author":"Grulich","year":"2007","journal-title":"Lancet"},{"key":"10.1053\/j.ajkd.2021.01.015_bib8","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1053\/j.ajkd.2011.07.015","article-title":"Lymphoproliferative disorders after adult kidney transplant: epidemiology and comparison of registry report with claims-based diagnoses","volume":"58","author":"Kasiske","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2021.01.015_bib9","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1002\/cncr.30923","article-title":"Contribution of solid organ transplant recipients to the pediatric non-hodgkin lymphoma burden in the United States","volume":"123","author":"Yanik","year":"2017","journal-title":"Cancer"},{"key":"10.1053\/j.ajkd.2021.01.015_bib10","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1111\/j.1600-6143.2011.03704.x","article-title":"Time trends in risk and risk determinants of non-Hodgkin lymphoma in solid organ transplant recipients","volume":"11","author":"Fernberg","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1053\/j.ajkd.2021.01.015_bib11","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/tri.12744","article-title":"Post-transplant lymphoproliferative disorder following kidney transplantation: a population-based cohort study","volume":"29","author":"Maksten","year":"2016","journal-title":"Transpl Int"},{"key":"10.1053\/j.ajkd.2021.01.015_bib12","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1111\/ajt.13324","article-title":"The impact of EBV status on characteristics and outcomes of posttransplantation lymphoproliferative disorder","volume":"15","author":"Luskin","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1053\/j.ajkd.2021.01.015_bib13","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/ajt.13558","article-title":"EBV-positive and EBV-negative posttransplant diffuse large B cell lymphomas have distinct genomic and transcriptomic features","volume":"16","author":"Fereiro","year":"2016","journal-title":"Am J Transplant"},{"key":"10.1053\/j.ajkd.2021.01.015_bib14","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/modpathol.2016.130","article-title":"EBV-negative monomorphic B-cell post-transplant lymphoproliferative disorders are pathologically distinct from EBV-positive cases and frequently contain TP53 mutations","volume":"29","author":"Courville","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1053\/j.ajkd.2021.01.015_bib15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12307-018-00219-5","article-title":"The Tumor microenvironment in post-transplant lymphoproliferative disorders","volume":"12","author":"Marcelis","year":"2019","journal-title":"Cancer Microenviron"},{"key":"10.1053\/j.ajkd.2021.01.015_bib16","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/TP.0b013e318277e344","article-title":"Characteristics of early and late PTLD development in pediatric solid organ transplant recipients","volume":"95","author":"Schober","year":"2013","journal-title":"Transplantation"},{"key":"10.1053\/j.ajkd.2021.01.015_bib18","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"453","article-title":"Post-transplant lymphoproliferative disorders","author":"Swerdlow","year":"2017"},{"key":"10.1053\/j.ajkd.2021.01.015_bib19","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/01.TP.0000055098.96022.F7","article-title":"Epstein-Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoroliferative disorder in adult renal allograft recipients","volume":"75","author":"Shahinian","year":"2003","journal-title":"Transplantation"},{"key":"10.1053\/j.ajkd.2021.01.015_bib17","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"issue":"suppl","key":"10.1053\/j.ajkd.2021.01.015_bib20","first-page":"S1","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients","volume":"9","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1053\/j.ajkd.2021.01.015_bib21","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13652","article-title":"Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Allen","year":"2019","journal-title":"Clin Transplant"},{"key":"10.1053\/j.ajkd.2021.01.015_bib22","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1097\/01.tp.0000235889.05171.12","article-title":"Association of human leukocyte antigen haplotypes with posttransplant lymphoproliferative disease after solid organ transplantation","volume":"82","author":"Subklewe","year":"2006","journal-title":"Transplantation"},{"key":"10.1053\/j.ajkd.2021.01.015_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10428194.2016.1173209","article-title":"Association between HLA-A1 and -A2 types and Epstein-Barr virus status of post-transplant lymphoproliferative disorder","volume":"57","author":"Kinch","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.ajkd.2021.01.015_bib24","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/TP.0000000000000469","article-title":"Peak panel reactive antibody, cancer, graft, and patient outcomes in kidney transplant recipients","volume":"99","author":"Lim","year":"2015","journal-title":"Transplantation"},{"key":"10.1053\/j.ajkd.2021.01.015_bib25","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1097\/TP.0000000000000375","article-title":"The risk of cancer in recipients of living-donor, standard and expanded criteria deceased donor kidney transplants: a registry analysis","volume":"98","author":"Ma","year":"2014","journal-title":"Transplantation"},{"key":"10.1053\/j.ajkd.2021.01.015_bib26","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/TP.0b013e3182782f59","article-title":"Effect of immunosuppression for primary renal disease on the risk of cancer in subsequent renal transplantation: a population-based retrospective cohort study","volume":"95","author":"Hibberd","year":"2013","journal-title":"Transplantation"},{"key":"10.1053\/j.ajkd.2021.01.015_bib27","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1111\/j.1600-6143.2007.01972.x","article-title":"Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab","volume":"7","author":"Kirk","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1053\/j.ajkd.2021.01.015_bib28","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1046\/j.1600-6135.2003.00274.x","article-title":"Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients","volume":"4","author":"Bustami","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1053\/j.ajkd.2021.01.015_bib29","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1097\/00007890-200104270-00010","article-title":"Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS)","volume":"71","author":"Dharnidharka","year":"2001","journal-title":"Transplantation"},{"key":"10.1053\/j.ajkd.2021.01.015_bib30","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.transproceed.2011.03.036","article-title":"Posttransplantation lymphoproliferative disorder in kidney and heart transplant recipients receiving thymoglobulin: a systematic review","volume":"43","author":"Marks","year":"2011","journal-title":"Transplant Proc"},{"key":"10.1053\/j.ajkd.2021.01.015_bib31","first-page":"CD010253","article-title":"Antibody induction versus placebo, no induction, or another type of antibody induction for liver transplant recipients","volume":"6","author":"Penninga","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.ajkd.2021.01.015_bib32","first-page":"CD008927","article-title":"Antibody induction therapy for lung transplant recipients","volume":"11","author":"Penninga","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.ajkd.2021.01.015_bib33","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1097\/01.TP.0000442773.38510.32","article-title":"Acute rejection, T-cell-depleting antibodies, and cancer after transplantation","volume":"97","author":"Lim","year":"2014","journal-title":"Transplantation"},{"key":"10.1053\/j.ajkd.2021.01.015_bib34","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/S0140-6736(05)80084-4","article-title":"Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients","volume":"342","author":"Opelz","year":"1993","journal-title":"Lancet"},{"key":"10.1053\/j.ajkd.2021.01.015_bib35","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1182\/blood-2009-02-202507","article-title":"Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation","volume":"114","author":"van Leeuwen","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.ajkd.2021.01.015_bib36","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1046\/j.1600-6143.2003.00325.x","article-title":"Lymphomas after solid organ transplantation: a collaborative transplant study report","volume":"4","author":"Opelz","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1053\/j.ajkd.2021.01.015_bib37","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1016\/j.transproceed.2008.09.025","article-title":"Cancer incidence and survival in kidney transplant patients","volume":"40","author":"Navarro","year":"2008","journal-title":"Transplant Proc"},{"key":"10.1053\/j.ajkd.2021.01.015_bib38","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1097\/00007890-199910270-00024","article-title":"Cytomegalovirus infection and posttransplant lymphoproliferative disease in renal transplant recipients: results of the U.S. multicenter FK506 Kidney Transplant Study Group","volume":"68","author":"Pirsch","year":"1999","journal-title":"Transplantation"},{"key":"10.1053\/j.ajkd.2021.01.015_bib39","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/bjh.14083","article-title":"Iatrogenic immunosuppression and risk of non-Hodgkin lymphoma in solid organ transplantation: a population-based cohort study in Australia","volume":"174","author":"Na","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1053\/j.ajkd.2021.01.015_bib40","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1111\/j.1600-6143.2005.01125.x","article-title":"Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil","volume":"5","author":"Robson","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1053\/j.ajkd.2021.01.015_bib41","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.leukres.2006.12.019","article-title":"Antiproliferative and apoptotic effects of mycophenolic acid in human B-cell non-Hodgkin lymphomas","volume":"31","author":"Vegso","year":"2007","journal-title":"Leuk Res"},{"key":"10.1053\/j.ajkd.2021.01.015_bib42","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/MOT.0b013e3283186ba9","article-title":"Epstein-Barr virus, rapamycin, and host immune responses","volume":"13","author":"Krams","year":"2008","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1053\/j.ajkd.2021.01.015_bib43","doi-asserted-by":"crossref","first-page":"774","DOI":"10.3109\/0284186X.2015.1130855","article-title":"Malignancies in transplanted patients: Multidisciplinary evaluation and switch to mTOR inhibitors after kidney transplantation - experiences from a prospective, clinical, observational study","volume":"55","author":"Hellstrom","year":"2016","journal-title":"Acta Oncol"},{"key":"10.1053\/j.ajkd.2021.01.015_bib44","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1399-0012.2004.00188.x","article-title":"Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies","volume":"18","author":"Mathew","year":"2004","journal-title":"Clin Transplant"},{"key":"10.1053\/j.ajkd.2021.01.015_bib45","doi-asserted-by":"crossref","first-page":"g6679","DOI":"10.1136\/bmj.g6679","article-title":"Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data","volume":"349","author":"Knoll","year":"2014","journal-title":"Br Med J"},{"key":"10.1053\/j.ajkd.2021.01.015_bib46","first-page":"CD010699","article-title":"Belatacept for kidney transplant recipients","volume":"11","author":"Masson","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.ajkd.2021.01.015_bib47","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1600-6143.2011.03785.x","article-title":"Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients","volume":"12","author":"Vincenti","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1053\/j.ajkd.2021.01.015_bib48","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1600-6143.2010.03016.x","article-title":"A\u00a0phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study)","volume":"10","author":"Durrbach","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1053\/j.ajkd.2021.01.015_bib49","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJMoa1506027","article-title":"Belatacept and long-term outcomes in kidney transplantation","volume":"374","author":"Vincenti","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2021.01.015_bib50","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1111\/j.1600-6143.2005.01115.x","article-title":"Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients","volume":"5","author":"Funch","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1053\/j.ajkd.2021.01.015_bib51","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(07)70040-2","article-title":"Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: a multicentre retrospective analysis","volume":"8","author":"Opelz","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.ajkd.2021.01.015_bib52","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/TP.0b013e31827df7a7","article-title":"Effect of cytomegalovirus immunoglobulin on the incidence of lymphoproliferative disease after lung transplantation: single-center experience with 1157 patients","volume":"95","author":"Jaksch","year":"2013","journal-title":"Transplantation"},{"key":"10.1053\/j.ajkd.2021.01.015_bib53","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.healun.2007.08.010","article-title":"Influence of induction therapy, immunosuppressive regimen and anti-viral prophylaxis on development of lymphomas after heart transplantation: data from the Spanish Post-Heart Transplant Tumour Registry","volume":"26","author":"Crespo-Leiro","year":"2007","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1053\/j.ajkd.2021.01.015_bib54","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/ajt.14020","article-title":"The role of antiviral prophylaxis for the prevention of Epstein-Barr virus-associated posttransplant lymphoproliferative disease in solid organ transplant recipients: a systematic review","volume":"17","author":"AlDabbagh","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1053\/j.ajkd.2021.01.015_bib55","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3324\/haematol.2010.023689","article-title":"The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders","volume":"95","author":"Merlo","year":"2010","journal-title":"Haematologica"},{"key":"10.1053\/j.ajkd.2021.01.015_bib56","doi-asserted-by":"crossref","first-page":"c570","DOI":"10.1136\/bmj.c570","article-title":"Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study","volume":"340","author":"van Leeuwen","year":"2010","journal-title":"Br Med J"},{"key":"10.1053\/j.ajkd.2021.01.015_bib57","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMra1702693","article-title":"Post-transplantation lymphoproliferative disorders in adults","volume":"378","author":"Dierickx","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2021.01.015_bib58","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1182\/blood-2006-01-024703","article-title":"A\u00a0phase 1\/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies","volume":"109","author":"Perrine","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.ajkd.2021.01.015_bib59","doi-asserted-by":"crossref","first-page":"4534","DOI":"10.1128\/JVI.02487-09","article-title":"The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production","volume":"84","author":"Meng","year":"2010","journal-title":"J\u00a0Virol"},{"key":"10.1053\/j.ajkd.2021.01.015_bib60","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S1470-2045(11)70300-X","article-title":"Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial","volume":"13","author":"Trappe","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.ajkd.2021.01.015_bib61","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1200\/JCO.2016.69.3564","article-title":"Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP consolidation in an international, prospective, multicenter phase II trial","volume":"35","author":"Trappe","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1053\/j.ajkd.2021.01.015_bib62","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1097\/TP.0000000000003183","article-title":"Real-world outcomes with rituximab-based therapy for posttransplant lymphoproliferative disease arising after solid organ transplantation","volume":"104","author":"Burns","year":"2020","journal-title":"Transplantation"},{"key":"10.1053\/j.ajkd.2021.01.015_bib63","doi-asserted-by":"crossref","first-page":"4583","DOI":"10.2147\/OTT.S141053","article-title":"Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review","volume":"11","author":"Donato","year":"2018","journal-title":"Onco Targets Ther"},{"key":"10.1053\/j.ajkd.2021.01.015_bib64","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1080\/0284186X.2020.1731924","article-title":"CD30 expression and survival in posttransplant lymphoproliferative disorders","volume":"59","author":"Kinch","year":"2020","journal-title":"Acta Oncol"},{"key":"10.1053\/j.ajkd.2021.01.015_bib65","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/ajt.15216","article-title":"Dual blockade of the PI3K\/Akt\/mTOR pathway inhibits posttransplant Epstein-Barr virus B cell lymphomas and promotes allograft survival","volume":"19","author":"Sang","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1053\/j.ajkd.2021.01.015_bib66","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1002\/1878-0261.12759","article-title":"The BCL-2 family protein inhibitor ABT-737 as an additional tool for the treatment of EBV-associated post-transplant lymphoproliferative disorders","volume":"14","author":"Robert","year":"2020","journal-title":"Mol Oncol"},{"key":"10.1053\/j.ajkd.2021.01.015_bib67","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1080\/10428194.2018.1480767","article-title":"Expression of PD-1, PD-L1, and PD-L2 in posttransplant lymphoproliferative disorder after solid organ transplantation","volume":"60","author":"Kinch","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.ajkd.2021.01.015_bib68","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1002\/cam4.2394","article-title":"PD-L1 and PD1 expression in post-transplantation lymphoproliferative disease (PTLD) of childhood and adolescence: An inter- and intra-individual descriptive study covering the whole spectrum of PTLD categories","volume":"8","author":"Schiefer","year":"2019","journal-title":"Cancer Med"},{"key":"10.1053\/j.ajkd.2021.01.015_bib69","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/his.13857","article-title":"Clinicopathological evaluation of the programmed cell death 1 (PD1)\/programmed cell death-ligand 1 (PD-L1) axis in post-transplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcome","volume":"75","author":"Veloza","year":"2019","journal-title":"Histopathology"},{"key":"10.1053\/j.ajkd.2021.01.015_bib70","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/ajt.13558","article-title":"EBV-positive and EBV-negative posttransplant diffuse large B cell lymphomas have distinct genomic and transcriptomic features","volume":"16","author":"Ferreiro","year":"2016","journal-title":"Am J Transplant"},{"key":"10.1053\/j.ajkd.2021.01.015_bib71","first-page":"865","article-title":"CAR-T therapy in solid organ transplant recipients with treatment refractory post transplant lymphoproliferative disorder","volume":"100","author":"Krishnamoorthy","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1053\/j.ajkd.2021.01.015_bib72","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1172\/JCI121127","article-title":"Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation","volume":"130","author":"Prockop","year":"2020","journal-title":"J\u00a0Clin Invest"},{"key":"10.1053\/j.ajkd.2021.01.015_bib73","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.kint.2018.06.009","article-title":"Post-transplant lymphoproliferative disease may be an adverse risk factor for patient survival but not graft loss in kidney transplant recipients","volume":"94","author":"Francis","year":"2018","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2021.01.015_bib74","doi-asserted-by":"crossref","first-page":"e369","DOI":"10.1097\/TP.0000000000002898","article-title":"Posttransplant lymphoproliferative disorder in pediatric patients: characteristics of disease in EBV-seropositive recipients","volume":"103","author":"L\u2019Huillier","year":"2019","journal-title":"Transplantation"},{"key":"10.1053\/j.ajkd.2021.01.015_bib75","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.3109\/10428194.2013.780655","article-title":"Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factors","volume":"54","author":"Dierickx","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.ajkd.2021.01.015_bib76","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2012.43.2344","article-title":"Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score","volume":"31","author":"Caillard","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1053\/j.ajkd.2021.01.015_bib77","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1200\/JCO.2009.25.4961","article-title":"Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era","volume":"28","author":"Evens","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1053\/j.ajkd.2021.01.015_bib78","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00277-007-0298-2","article-title":"Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution","volume":"86","author":"Choquet","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1053\/j.ajkd.2021.01.015_bib79","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1200\/JCO.2001.19.3.772","article-title":"Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders","volume":"19","author":"Leblond","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1053\/j.ajkd.2021.01.015_bib80","first-page":"987","article-title":"A\u00a0predictive model for aggressive non-Hodgkin\u2019s lymphoma. The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project","volume":"329","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2021.01.015_bib81","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1200\/JCO.2013.50.3326","article-title":"Validation of prognostic scores in post-transplantation lymphoproliferative disorders","volume":"31","author":"Dierickx","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1053\/j.ajkd.2021.01.015_bib82","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/ajt.13086","article-title":"International prognostic index, type of transplant and response to rituximab are key parameters to tailor treatment in adults with CD20-positive B cell PTLD: clues from the PTLD-1 trial","volume":"15","author":"Trappe","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1053\/j.ajkd.2021.01.015_bib83","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/ki.2013.253","article-title":"Maintaining calcineurin inhibition after the diagnosis of post-transplant lymphoproliferative disorder improves renal graft survival","volume":"85","author":"Serre","year":"2014","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2021.01.015_bib84","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1111\/j.1600-6143.2009.02772.x","article-title":"Treatment of PTLD with rituximab and CHOP reduces the risk of renal graft impairment after reduction of immunosuppression","volume":"9","author":"Trappe","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1053\/j.ajkd.2021.01.015_bib85","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2215\/CJN.03790417","article-title":"A\u00a0French cohort study of kidney retransplantation after post-transplant lymphoproliferative disorders","volume":"12","author":"Caillard","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2021.01.015_bib86","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/ajt.16385","article-title":"Outcomes of kidney retransplantation in recipients with prior post-transplant lymphoproliferative disorders: an analysis of the 2000-2019 UNOS\/OPTN database","volume":"21","author":"Leeaphorn","year":"2021","journal-title":"Am J Transplant"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638621005011?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638621005011?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:38:32Z","timestamp":1759462712000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638621005011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0272638621005011"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2021.01.015","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Posttransplant Lymphoproliferative Disorder Following Kidney Transplantation: A Review","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2021.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}